Accumetrics Closes 2009 with Positive Outlook

By Accumetrics Inc., PRNE
Monday, December 14, 2009

New distribution agreements, favorable clinical data, and significant capital financing position the company for continued growth in 2010

SAN DIEGO, December 15 - Accumetrics, Inc., developer and marketer of the VerifyNow(R) System, the
first rapid and easy-to-use diagnostic system for measuring an individual's
response to multiple antiplatelet agents, announced that 2009 included a
doubling in the number of international and U.S. distribution agreements, as
well as positive medical community support, and significant capital financing
that will take the company into 2011.

In 2009, the company continued its commitment to creating a powerful,
worldwide distribution network aimed at gaining adoption of its products at
end-user levels. Spanning Europe, Latin America and Asia, Accumetrics
currently has partnerships with 20 leading international distributors who
provide the company with local representation in over 30 countries. Latest
additions to the international distribution network include Keller Medical in
Germany, ZAO "Schag" in Russia and VSA Alta Complejidad S.A. in Argentina.

Accumetrics continued to strengthen its U.S. presence by partnering with
10 cardiovascular specialty distributors to enhance support to the company's
growing base of clinicians in the domestic hospital market. Accumetrics has
also partnered with National Distribution & Contracting, Inc. (NDC), the
largest organization of independent medical supply distributors in North
, to expand its distribution network in the physician office lab

Increasing evidence of the clinical value of platelet reactivity testing
was demonstrated in several presentations of new clinical studies including
the POPular study, presented at the American Heart Association Scientific
Sessions in November, and a meta-analysis presented at a symposium during the
2009 Transcatheter Cardiovascular Therapeutics (TCT ) Conference. These data
also build upon the anticipation of the results of the GRAVITAS trial, which
has now completed 80% enrollment.

"2009 has proven to be an outstanding year of growth for Accumetrics,"
said Timothy I. Still, CEO and President of Accumetrics. "We look at 2010 as
a breakthrough year for the company, and are pleased to be in a position to
capitalize on the growing clinical acceptance of platelet reactivity

Accumetrics concluded 2009 with US$17.1 million in new capital financing,
which will fully support the company into 2011. Proceeds will fund a number
of key 2010 milestones including expanded claims for existing products, new
product development and continued expansion of commercialization efforts.

About Accumetrics (

Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic
tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform
for measuring an individual's response to multiple antiplatelet agents.
Addressing every major antiplatelet drug, including FDA-cleared products for
aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient(TM)) and clopidogrel
(Plavix(R))), and the GP IIb/IIIa inhibitors (e.g. ReoPro(R) and
Integrilin(R)), the VerifyNow System provides a valuable tool to help
physicians make more informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is
a registered trademark of sanofi-aventis. Effient is a trademark of Eli Lilly
and Company.

    Megan Rusnack
    Lippert/Heilshorn & Associates


    Timothy I. Still
    President and CEO

Megan Rusnack of Lippert/Heilshorn & Associates, +1-212-838-3777, mrusnack at, for Accumetrics, Inc.; or Timothy I. Still, President and CEO, Accumetrics, +1-858-404-8260, press at

will not be displayed